Non-alcoholic hepatosteatosis (NASH) is a serious chronic disease
that is becoming increasingly prevalent1;2. Highlighting
the interrelated links3 between NASH and other metabolic
diseases3, around two thirds1 of those living
with type 2 diabetes are believed to also have NASH, and many have
obesity as well. NASH is a progressed stage of non-alcoholic fatty
liver disease (NAFLD).
At the moment, NASH is without effective pharmacotherapeutic
interventions4 and to make matters worse, timely diagnosis
of the disease has traditionally been exceedingly difficult due to the
lack of non-invasive tests such as blood-based biomarkers. Thus, at
clinical debut, people with NASH frequently present2 with
wide-spread hepatosteatosis and reduced liver function due to fibrosis
or even cirrhosis. Severe outcomes also include liver failure, liver
cancer and cardiovascular disease.
Novo Nordisk is heavily invested in improving the diagnosis and
treatment of NASH. We have multiple ongoing efforts to identify
validated biomarkers and to test potential therapies such as
semaglutide (GLP-1 RA) alone or in combination with FGF-21 or other
compounds. Working closely with our peers and partners, we also
contribute to relevant liver-focused consortia and collaborate with
academic groups on translational endeavours.
Thankfully, new advances in the understanding of how to best
diagnose and ameliorate NASH are continuously reported. We welcome you
to use the NASH
area of ScienceHub to stay updated on relevant articles and
congresses. Below, we introduce a selection of recent publications and
congresses that we invite you to explore, including the accompanying
easy-to-approach audio-visual presentations.